Helius Medical receives compliance letter from Nasdaq

Helius Medical (HSDT) Technologies announced that on July 7 Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550 for continued listing on the Nasdaq Capital Market. As previously disclosed, on June 3 the Company received formal notification from Nasdaq confirming that the Company had regained compliance with the minimum bid price requirement, as set forth in Nasdaq Marketplace Rule 5550. The Company is currently in full compliance with NASDAQ continued listing requirements.